pharmaceuticals Limited
Registered & Corporate Office :
8th Floor, Trendset Jayabheri Connect,
Kondapur, Hyderabad - 500 084,
Telangana, India.
Tel : +91 - 40 - 6985 9999
CIN No. : L24239TG1987PLC008066
Email : info@smspharma.com, www.smspharma.com

Date: 30th October, 2026

To

Corporate Filings Department,
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai- 400 001.

Listing Compliance Department,
National Stock Exchange of India Ltd.
Exchange Plaza, Plot no. C/1, G Block,
Bandra-Kurla Complex, Bandra (E),
Mumbai - 400 051.

Security Code: 532815

Symbol: SMSPHARMA

Dear Sir/Madam,

Subject: Disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

This is further to our letter dated July 31, 2026, and in compliance with Regulation 30 read with Schedule III of Listing Regulations, we hereby inform you that the Company has entered into a Loan Agreement with SMS Peptides Private Limited, a subsidiary of the Company.

The details as required in terms of Regulation 30 and Schedule III of the SEBI Listing Regulations, read with SEBI Circular SEBI/HO/49/14/14(7)2025-CFDPOD2/I/3762/2026 dated January 30, 2026 are enclosed as **Annexure -A.**

Please take the above intimation on your records.

Thanking you
Yours faithfully

For SMS Pharmaceuticals Limited

THIRUMALESH TUMMA

Digitally signed by THIRUMALESH TUMMA
Date: 2026.10.30 16:50:27 +05'30'

Thirumalesh Tumma
Company Secretary & Compliance Officer

Annexure -A

Sr. No.	Particulars	Details
1.	Name(s) of parties with whom the agreement is entered	Loan Agreement has been entered between SMS Pharmaceuticals Limited (Company/ SMS Pharma/Lender) and SMS Peptides Private Limited (SMS Peptides/Borrower), a Subsidiary of the Company
2.	Purpose of entering into the agreement	The Company has entered a loan agreement with SMS Peptides Private Limited a Subsidiary of the Company to provide loan to subsidiary company for its business purpose.
3.	Size of agreement	Up to an aggregate amount not exceeding Rs. 50 Crores, in one or more trenches.
4.	Shareholding, if any, in the entity with whom the agreement is executed	The Company is holding 99.99% stake in the SMS Peptides as on date.
5.	Significant terms of the agreement (in brief) special rights like right to appoint directors, first right to share subscription in case of issuance of shares, right to restrict any change in capital structure etc	No such special rights
6.	Whether, the said parties are related to promoter/promoter group/ group companies in any manner. If yes, nature of relationship	Yes, SMS peptides is the Subsidiary of SMS pharma having common Directors
7.	Whether the transaction would fall within related party transactions? If yes, whether the same is done at "arm's length"	Yes, the transaction is at arm's length basis.
8.	In case of issuance of shares to the parties, details of issue price, class of shares issued	Not Applicable
9.	In case of loan agreements, details of lender/borrower, nature of the loan, total amount of loan granted/taken, total amount outstanding, date of execution of the loan agreement/sanction letter, details of the security provided to the lenders / by the borrowers for such loan or in case outstanding loans lent to a party or borrowed from a party become material on a cumulative basis	Lender: SMS Pharmaceuticals Limited Borrower: M/s. SMS Peptides Private Limited Nature of loan: Unsecured loan Amount of loan: Up to an aggregate amount not exceeding Rs. 50 Crores (Rupees Fifty Crore Only) Date of execution of Loan Agreement: 30th October, 2026 Amount of loan outstanding as on date of disclosure – Nil
10.	Any other disclosures related to such agreements, viz., details of nominee	NIL

	on the board of directors of the listed entity, potential conflict of interest arising out of such agreements, etc	
11.	In case of termination or amendment of agreement, listed entity shall disclose additional details to the stock exchange(s): i. name of parties to the agreement; ii. nature of the agreement; iii. date of execution of the agreement; iv. details of amendment and impact thereof or reasons of termination and impact thereof	Not Applicable